Detalhe da pesquisa
1.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
HIV Med
; 25(3): 381-390, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38147871
2.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134313
3.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660819
4.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945163
5.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411596
6.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Antimicrob Agents Chemother
; 66(2): e0091621, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871089
7.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308425
8.
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Ann Hepatol
; 15(4): 512-23, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27236150
9.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538161
10.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538160
11.
Pharmacokinetic interaction between telaprevir and methadone.
Antimicrob Agents Chemother
; 57(5): 2304-9, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23478952
12.
Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
Int J Clin Pharmacol Ther
; 51(9): 725-37, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924679
13.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567205
14.
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
J Acquir Immune Defic Syndr
; 91(1): 73-78, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551149
15.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS
; 36(2): 185-194, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261093
16.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Antivir Ther
; 26(6-8): 95-105, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35485339
17.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient
; 14(6): 849-862, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34056699
18.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV
; 8(11): e668-e678, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656207
19.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648734
20.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794181